Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
暂无分享,去创建一个
Lynn Morris | Yan Liu | Michael S. Seaman | Florian Klein | Ten Feizi | Pascal Poignard | Clara Lehmann | Johannes F. Scheid | Michel C. Nussenzweig | B. Walker | L. Stamatatos | M. Nussenzweig | A. Hurley | L. Morris | Z. Kraft | D. Sather | P. Poignard | H. Mouquet | C. Lehmann | G. Fätkenheuer | M. Seaman | Bruce D. Walker | J. Scheid | J. Pietzsch | Hugo Mouquet | John Pietzsch | F. Klein | C. Gaebler | T. Feizi | Arlene Hurley | Yan Liu | Gerd Fätkenheuer | Leonidas Stamatatos | Christian Gaebler | D. Noah Sather | Zane Kraft
[1] L. Stamatatos,et al. Characterization of Neutralizing Antibody Responses Elicited by Clade A Envelope Immunogens Derived from Early Transmitted Viruses , 2008, Journal of Virology.
[2] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[3] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[4] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[5] L. Stamatatos,et al. Binding Interactions between Soluble HIV Envelope Glycoproteins and Quaternary-Structure-Specific Monoclonal Antibodies PG9 and PG16 , 2011, Journal of Virology.
[6] M. Nussenzweig,et al. Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.
[7] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[8] L. Stamatatos,et al. Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles , 2005, Journal of Virology.
[9] Michel C Nussenzweig,et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.
[10] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[11] Ron Diskin,et al. Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.
[12] D. Burton,et al. Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.
[13] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[14] Richard T. Wyatt,et al. Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.
[15] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[16] Mario Roederer,et al. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.
[17] S. Gordon,et al. Ligands for the β-Glucan Receptor, Dectin-1, Assigned Using “Designer” Microarrays of Oligosaccharide Probes (Neoglycolipids) Generated from Glucan Polysaccharides* , 2006, Journal of Biological Chemistry.
[18] L. Stamatatos,et al. Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region , 2003, Journal of Virology.
[19] Yan Liu,et al. A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.
[20] Persephone Borrow,et al. The immune response during acute HIV-1 infection: clues for vaccine development , 2009, Nature Reviews Immunology.
[21] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] Hanneke Schuitemaker,et al. Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[23] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.
[24] Pascal Poignard,et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.
[25] L. Morris,et al. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.
[26] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[27] M. Nussenzweig,et al. Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses , 2011, PloS one.
[28] S. Zolla-Pazner,et al. Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes , 2009, PloS one.
[29] Susan Moir,et al. Prospects for an HIV vaccine: leading B cells down the right path , 2011, Nature Structural &Molecular Biology.
[30] W. Chai,et al. Neoglycolipid-based oligosaccharide microarray system: preparation of NGLs and their noncovalent immobilization on nitrocellulose-coated glass slides for microarray analyses. , 2012, Methods in molecular biology.
[31] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[32] J. Albert,et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.
[33] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[34] T. Kepler,et al. Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting , 2011, PloS one.
[35] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[36] David C Montefiori,et al. The role of antibodies in HIV vaccines. , 2010, Annual review of immunology.
[37] A. Trkola,et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.
[38] Dennis R. Burton,et al. A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.
[39] T. Kepler,et al. Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design , 2012, Journal of Virology.
[40] F. Pereyra,et al. A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.
[41] Q. Sattentau,et al. Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.
[42] L. Morris,et al. The Antibody Response against HIV-1. , 2012, Cold Spring Harbor perspectives in medicine.
[43] L. Stamatatos,et al. The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner , 2005, Journal of Virology.
[44] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[45] Maxim N. Artyomov,et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.
[46] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[47] T. Kepler,et al. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.
[48] D. Montefiori,et al. Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.
[49] M. Nussenzweig,et al. Human anti–HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness , 2010, The Journal of experimental medicine.
[50] H. Mouquet,et al. Proteomic analysis of the autoantibody response following immunization with a single autoantigen , 2006, Proteomics.
[51] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[52] M. Altfeld,et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.
[53] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[54] Guido Ferrari,et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.
[55] Lynn Morris,et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.
[56] N. Haigwood,et al. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.
[57] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[58] H. Wigzell. Prospects for an HIV‐vaccine , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[59] A. Trkola,et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.